Navigation Links
NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
Date:9/19/2007

d clinical and translational researcher with more than 25 years of NIH funding, Dr. Imperato-McGinley will also be named the associate dean for educational training and translational research at Weill Cornell. In addition, she is the Abby Rockefeller Mauz Distinguished Professor of Medicine in Endocrinology, Diabetes and Metabolism.

"Together with our collaborator-institutions, we will work toward moving translational research from bench to bedside to community," continues Dr. Imperato-McGinley. "Furthermore, in a process of circular innovation, lessons learned in the community will then be the basis for new research efforts."

An extensive community outreach program, especially for ethnically diverse medically underserved areas, will be an important component of the CTSC initiative. Member institutions, particularly the Cornell University Cooperative Extension, have existing partnerships with key community organizations.

The initiative will target the full range of clinical areas, among them -- cancer, diabetes, AIDS, cardiovascular disease, women's health, reproductive medicine, geriatrics, psychiatry, Alzheimer's disease, kidney disease, obesity, multiple sclerosis, neuromuscular disorders, trauma and burns.

Neighboring institutions will contribute significantly to the CTSC: The Hospital for Special Surgery -- one of the most renowned orthopedic hospitals in the U.S. and a leader in investigating musculoskeletal and autoimmune diseases -- is one of two medical institutions designated by NIH as a Core Center for Skeletal Integrity. Memorial Sloan-Kettering Cancer Center represents one of the world's premier cancer centers where state-of-the-art basic science research flourishes side-by-side with clinical investigation and treatment at Memorial Hospital. Cornell University Cooperative Extension has been engaged in research addressing the needs of a changing New York for over 50 years, and will remain a significant linchpin for c
'/>"/>

Contact: Jonathan Weil
jweil@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. United States Department of Defense Selects Ichor Medical Systems to Develop Biodefense Vaccine
2. Researchers at Cornell University as been reported using research fund by false claims
3. Family Turmoil and Violence Results in Stress-induced Physical Problems in Young, Cornell Psychologist Finds
4. Check if your “Favourite medical web-site” is indulging in Quackey
5. Teens turning to Internet for medical queries
6. Robots craft medical history
7. NBE to conduct test for medical students from abroad
8. Air pollution combined with greater medical needs
9. Indian Nationals with Foreign Medical Degrees can now practice in India
10. Children! Protecting them from medical mistakes
11. More information sought by patients on medical errors
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 2Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 3Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6